Business Context and Reporting Period
Lifemd, Inc. (LFMD) is a patient-centric, direct-to-patient healthcare company providing virtual medical care and pharmacy services through brands including LifeMD, RexMD, and ShapiroMD. This Form 10-Q covers the quarterly period ended March 31, 2026. The company operates as a single segment and recently sold its majority interest in WorkSimpli, which is now classified as discontinued operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 (Revised) |
|---|---|---|
| Telehealth Revenue, Net | $50.16 million | $50.89 million |
| Gross Profit | $44.24 million | $42.75 million |
| Gross Margin | 88.2% | 84.0% |
| Operating Loss | $(8.93) million | $(1.18) million |
| Net Loss (Continuing Ops) | $(8.87) million | $(1.65) million |
| Net Loss Attributable to Common Stockholders | $(9.65) million | $(0.96) million |
| Diluted Loss Per Share | $(0.20) | $(0.02) |
| Cash and Cash Equivalents | $34.48 million | $34.39 million |
| Working Capital | $2.11 million | $10.26 million (Dec 31, 2025) |
| Net Cash Provided by Operating Activities | $0.44 million | $3.07 million |
Material Changes vs. Prior Period
- Revenue: Net telehealth revenue decreased 1.4% to $50.16 million. This was driven by a $1.0 million decrease in telehealth product revenue, partially offset by a $0.28 million increase in subscription revenue.
- Expenses: Total operating expenses increased 21% to $53.17 million.
- Selling and Marketing: Increased 34% ($7.6 million) to $29.87 million due to aggressive initiatives to drive sales growth.
- General and Administrative: Increased 5.8% ($0.84 million) primarily due to higher compensation costs and legal fees, partially offset by lower stock-based compensation.
- Profitability: Operating loss widened significantly from $1.18 million to $8.93 million, primarily due to the surge in marketing spend.
- Liquidity: Working capital decreased by $8.1 million to $2.11 million, driven by a $2.3 million decrease in cash and an $8.0 million increase in current liabilities (notably accounts payable and deferred revenue).
Outlook, Risks, and Contingencies
- Covenant Compliance: The company is currently out of compliance with the Consolidated Interest Coverage Ratio covenant of its $30 million Citizens Bank Credit Facility. This is attributed to the 34% increase in selling and marketing costs. Discussions regarding a waiver or amendment are ongoing. No amounts have been drawn on the facility.
- Liquidity Outlook: Management expects existing cash ($34.5 million) and proceeds from the At-Market (ATM) issuance agreement ($44.6 million available) to fund operations for at least the next 12 months.
- Legal Proceedings: A putative securities class action lawsuit (Johnston v. LifeMD, Inc.) and four shareholder derivative complaints are pending. The company intends to defend against these claims vigorously.
- Internal Controls: The company disclosed that disclosure controls and procedures were not effective as of March 31, 2026, due to material weaknesses in revenue recognition controls, segregation of duties, and IT general controls. A remediation plan is in progress.
- Discontinued Operations: WorkSimpli was sold in November 2025. Results for Q1 2025 have been recast to reflect discontinued operations.
Investor Verification Checklist
- Verify the status of the waiver or amendment for the Citizens Bank Credit Facility covenant breach.
- Monitor the progress of the remediation plan for material weaknesses in internal controls over financial reporting.
- Assess the return on investment for the 34% increase in selling and marketing expenses in future quarters.
- Review the timeline and potential impact of the pending securities class action and derivative lawsuits.
- Confirm the utilization of the ATM Sales Agreement to maintain liquidity given the operating losses.